

Press Release  
31 January 2022 16:45:00 CET



## Newbury Pharmaceuticals publishes a supplementary document prior to scheduled listing on Nasdaq First North Growth Market

**Due to the planned listing on Nasdaq First North Growth Market, Newbury Pharmaceuticals AB (publ) ("Newbury" or "the Company") has today prepared a supplementary document which is available on Newbury's website, [www.newburypharma.com](http://www.newburypharma.com).**

The supplementary document contains certain information regarding the capitalization structure, net indebtedness and ownership structure related to Newbury and reflects the Company after the new share issue (the "Offer"). The supplementary document also contains some additional information which means that Newbury meets the requirements set out in the Nasdaq First North Rulebook.

The supplementary document shall be read as a supplement to the prospectus that the Company published on January 11, 2022, in connection with the Offer. The supplementary document is not a prospectus, has not been reviewed or approved by any supervisory authority and does not contain any offer of shares or other financial instruments.

Newbury has previously received a preliminary and conditional notice from Nasdaq that the Company meets the listing requirements, with customary conditions and reservations. The first day of trading on Nasdaq First North Growth Market is scheduled for February 4, 2022, under the short name NEWBURY.

### **For more information, contact:**

---

Lars Minor, CEO  
[lars.minor@newburypharma.com](mailto:lars.minor@newburypharma.com)  
Mobile: +46 72-377 3005

[www.newburypharma.com](http://www.newburypharma.com)

### **About Newbury Pharmaceuticals**

---

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.

Press Release  
31 January 2022 16:45:00 CET



## Attachments

---

[Newbury Pharmaceuticals publishes a supplementary document prior to scheduled listing on Nasdaq First North Growth Market](#)